CA2837892A1 - Tem8 antibodies, conjugates thereof, and their use - Google Patents

Tem8 antibodies, conjugates thereof, and their use Download PDF

Info

Publication number
CA2837892A1
CA2837892A1 CA2837892A CA2837892A CA2837892A1 CA 2837892 A1 CA2837892 A1 CA 2837892A1 CA 2837892 A CA2837892 A CA 2837892A CA 2837892 A CA2837892 A CA 2837892A CA 2837892 A1 CA2837892 A1 CA 2837892A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2837892A
Other languages
English (en)
French (fr)
Inventor
Brad St. Croix
Tony Fleming
Amit Chaudhary
Saurabh Saha
Xiaoyan Michelle ZHANG
Rou-fun KWONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
United States Department of Health and Human Services
Original Assignee
Novartis AG
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, United States Department of Health and Human Services filed Critical Novartis AG
Publication of CA2837892A1 publication Critical patent/CA2837892A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2837892A 2011-06-14 2012-06-13 Tem8 antibodies, conjugates thereof, and their use Abandoned CA2837892A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161496986P 2011-06-14 2011-06-14
US201161496737P 2011-06-14 2011-06-14
US61/496,737 2011-06-14
US61/496,986 2011-06-14
PCT/US2012/042315 WO2012174160A1 (en) 2011-06-14 2012-06-13 Tem8 antibodies, conjugates thereof, and their use

Publications (1)

Publication Number Publication Date
CA2837892A1 true CA2837892A1 (en) 2012-12-20

Family

ID=47357454

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837892A Abandoned CA2837892A1 (en) 2011-06-14 2012-06-13 Tem8 antibodies, conjugates thereof, and their use

Country Status (5)

Country Link
US (1) US9181340B2 (enExample)
EP (1) EP2721071A4 (enExample)
JP (1) JP2014524902A (enExample)
CA (1) CA2837892A1 (enExample)
WO (1) WO2012174160A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012065161A2 (en) 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
US20160015750A1 (en) * 2013-03-09 2016-01-21 Baylor College Of Medicine Vascular-targeted t-cell therapy
US9862951B2 (en) 2013-06-14 2018-01-09 Texas Tech University System RNA interference-based therapeutic against anthrax
EP3054987B1 (en) * 2013-10-11 2019-10-09 The United States of America, represented by the Secretary, Department of Health and Human Services Tem8 antibodies and their use
JP6795877B2 (ja) * 2013-12-25 2020-12-02 東京応化工業株式会社 表面被覆膜の形成方法及び表面被覆膜を有する太陽電池
US11033621B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
WO2015191568A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US10758526B2 (en) * 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US10758614B2 (en) * 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191596A1 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
WO2015191617A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
WO2015191615A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
WO2017139498A1 (en) * 2016-02-09 2017-08-17 Cour Pharmaceuticals Development Company Inc. Timps encapsulating japanese cedar pollen epitopes
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
CN108707199A (zh) * 2018-05-29 2018-10-26 廊坊康宝汇泰生物技术有限公司 靶向tem8的嵌合抗原受体t细胞及其应用
CN121419992A (zh) * 2023-05-31 2026-01-27 应世生物科技(南京)有限公司 一种靶向tem8的抗体或其抗原结合片段及其应用
AU2025225534A1 (en) * 2024-02-23 2026-08-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of cardiovascular disease with antxr1 antibodies
WO2026165109A1 (en) * 2025-01-28 2026-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tem8 monoclonal antibodies and their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810195B1 (fr) 2000-06-16 2002-08-30 Kuhn Audureau Sa Machine de coupe pouvant etre accrochee a un tracteur et comprenant un mecanisme de coupe a rotor et couteaux perfectionne
WO2002010217A2 (en) 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
DE60128008T2 (de) 2000-12-05 2008-01-10 Wisconsin Alumni Research Foundation, Madison Rezeptor für ein toxin aus bacillus anthracis
JP2004533825A (ja) 2001-04-11 2004-11-11 ザ ジョンズ ホプキンス ユニバーシティ 内皮細胞発現パターンの評価法
AU2003281867A1 (en) 2002-03-28 2004-02-23 University Of Florida Antisense nucleic acids
CN1832965B (zh) 2003-03-04 2011-03-02 麒麟麦酒株式会社 内皮细胞特异性抗体及其用途
WO2005038022A1 (ja) * 2003-10-20 2005-04-28 Teijin Pharma Limited 骨及び／又は関節疾患関連遺伝子
WO2005081749A2 (en) 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
ITRM20060337A1 (it) 2006-06-27 2007-12-28 Biosoot Srl Gene tem8 (tumor endotelial marker 8) e sue forme di espressione ed usi diagnostici e terapeutici
CN101591395A (zh) * 2009-07-13 2009-12-02 杭州屹源生物技术有限公司 抗人肿瘤血管内皮标志分子8胞外区的人源性单链抗体及其应用
WO2012065161A2 (en) * 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8

Also Published As

Publication number Publication date
EP2721071A4 (en) 2015-01-21
WO2012174160A1 (en) 2012-12-20
US20140134179A1 (en) 2014-05-15
US9181340B2 (en) 2015-11-10
EP2721071A1 (en) 2014-04-23
JP2014524902A (ja) 2014-09-25

Similar Documents

Publication Publication Date Title
US9181340B2 (en) TEM8 antibodies, conjugates thereof, and their use
AU2023251389B2 (en) Tem8 antibodies and their use
US10035853B2 (en) Site-specific antibody conjugation methods and compositions
US20160175460A1 (en) Engineered anti-dll3 conjugates and methods of use
US20140328841A1 (en) Anti-ceacam1 recombinant antibodies for cancer therapy
US12565532B2 (en) Monoclonal antibodies that bind EGFRvIII and their use
AU2012271645A1 (en) TEM8 antibodies, conjugates thereof, and their use
HK40102376A (en) Tem8 antibodies and their use
HK40023072A (en) Tem8 antibodies and their use
HK40023072B (en) Tem8 antibodies and their use
WO2025014896A1 (en) Humanized 40h3 antibody

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20180613